Abstract:
AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible studies, 11 studies were included. For PD-L1 >1% patients versus PD-L1 <1% patients treated with PD-1/PD-L1 targeted agents, the OR of ORR was 2.81 (95% CI: 1.64-4.82; p = 0.0002); while for PD-L1 >5% patients versus PD-L1 <5% patients, it was 2.22 (95% CI: 1.71-2.87; p < 0.00001). CONCLUSION:The current analysis indicates the value of PD-L1 positivity in predicting higher response from PD-1/PD-L1 agents. This molecular predictor - together with other predictors - may help further individualize treatment options for metastatic melanoma patients.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Abdel-Rahman Odoi
10.2217/imt-2016-0025subject
Has Abstractpub_date
2016-09-01 00:00:00pages
1081-9issue
9eissn
1750-743Xissn
1750-7448journal_volume
8pub_type
杂志文章,meta分析相关文献
Immunotherapy文献大全abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0029
更新日期:2017-06-01 00:00:00
abstract::Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0178
更新日期:2018-06-01 00:00:00
abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.20
更新日期:2012-04-01 00:00:00
abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.17
更新日期:2013-04-01 00:00:00
abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0105
更新日期:2019-02-01 00:00:00
abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0052
更新日期:2016-10-01 00:00:00
abstract::Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.14.44
更新日期:2014-01-01 00:00:00
abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.66
更新日期:2015-01-01 00:00:00
abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.103
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.120
更新日期:2013-11-01 00:00:00
abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2016-0068
更新日期:2016-10-01 00:00:00
abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...
journal_title:Immunotherapy
pub_type: 面试,新闻
doi:10.2217/imt.13.27
更新日期:2013-05-01 00:00:00
abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.68
更新日期:2013-08-01 00:00:00
abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.36
更新日期:2009-07-01 00:00:00
abstract::Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.39
更新日期:2011-04-01 00:00:00
abstract::Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.68
更新日期:2010-11-01 00:00:00
abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0051
更新日期:2017-09-01 00:00:00
abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0006
更新日期:2020-08-01 00:00:00
abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.26
更新日期:2014-01-01 00:00:00
abstract::The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...
journal_title:Immunotherapy
pub_type: 总体
doi:10.2217/imt.11.90
更新日期:2011-08-01 00:00:00
abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0134
更新日期:2017-12-01 00:00:00
abstract::Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.12.143
更新日期:2013-01-01 00:00:00
abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2018-0144
更新日期:2019-04-01 00:00:00
abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0019
更新日期:2017-05-01 00:00:00
abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.43
更新日期:2010-09-01 00:00:00
abstract::Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.61
更新日期:2014-01-01 00:00:00
abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.47
更新日期:2013-07-01 00:00:00
abstract::Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.12.116
更新日期:2012-11-01 00:00:00
abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0027
更新日期:2017-08-01 00:00:00
abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.10.41
更新日期:2010-07-01 00:00:00